Best Diversified Bank Stocks For 2015

In April, the automotive industry's seasonally adjusted annual rate of sales, or SAAR, dropped below 15 million for the first time this year. When sales numbers came in at 14.9 million for the month, some investors began sounding warning alarms that vehicle sales could be in for a decline for the rest of 2013. I didn't buy into those headlines, and it looks like strong sales are here to stay. May sales bounced back to 15.3 million and the graph below shows recent strength in SAAR numbers.�

Ford (NYSE: F  ) had an excellent month, and there were bright spots for its crosstown rival�General Motors (NYSE: GM  ) . Let's take a look at some of last month's biggest winners.

Winner, winner!
The industry grew 8% in May led by Nissan, Ford, and Chrysler which gained 25%, 14%, and 11%, respectively. Those trailing industry growth were Honda (NYSE: HMC  ) and Volkswagen at 5% and 4%, respectively. Even further behind were Toyota (NYSE: TM  ) and General Motors, reporting 3% gains.�

Best Diversified Bank Stocks For 2015: Cytomedix Inc (CMXI)

Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.

The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. Its clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.

The AutoloGel System

The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient�� own blood. Using the patient�� own platelets as a therapeutic agent, AutoloGel harnesses the body�� natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.

Angel Product Line

The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care device for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient�� own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.

ALDHbr Cell Technology and Development Pipeline

The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient�� bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.

The Company�� lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia (CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.

The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.

Advisors' Opinion:

• [By Bryan Murphy]

  When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient's on body to do what it's supposed to do if there's a wound that won't heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There's a relatively new name to add to the list of game-changing stocks in wound-management industry, however.... Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing - well, has developed - a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.

• [By James E. Brumley]

  To give credit where it's due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts "up a notch", however, and its direct solution to a problem that CMXI and BAX can't quite solve may make ARTH the hottest trading candidate in the hemostasis space.

Best Diversified Bank Stocks For 2015: Intralinks Holdings Inc (IL)

IntraLinks Holdings, Inc. (IntraLinks), incorporated in June 1996, together with its subsidiaries, is a global provider of Software-as-a-Service (SaaS) solutions for securely managing content, exchanging critical business information and collaborating within and among organizations. The Company�� cloud-based solutions enable organizations to control, track, search and exchange time-sensitive information inside and outside the firewall, all within a secure environment. The Company provide services to enterprises and governmental agencies in over 60 countries across a variety of industries, including financial services, pharmaceutical, biotechnology, consumer, energy, industrial, legal, insurance, real estate and technology. The Company sells its solutions directly through an enterprise sales team with industry-specific expertise and indirectly through a customer referral network and channel partners. In April 2013, it acquired MergerID. Concurrently, IntraLinks acquired PE-Nexus LLC.

The Company delivers its solutions through a cloud-based model where they are available on-demand over the Internet using a multi-tenant SaaS architecture in which a single instance of its software serves all of its customers. The Company provides its customers with various services, including access to its cloud-based IntraLinks Platform, access to one or more of its intraLinks exchanges, and related customer support and other services.

The Company competes with Merrill Corporation, RR Donnelley & Sons Company, EMC Corporation and International Business Machines Corp. (IBM).

Advisors' Opinion:

• [By Seth Jayson]

  IntraLinks Holdings (NYSE: IL  ) reported earnings on May 8. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), IntraLinks Holdings beat expectations on revenues and met expectations on earnings per share.

• [By Lee Jackson]

  IntraLinks Holdings Inc. (NYSE: IL) is a leading global software as a service (SaaS) provider of inter-enterprise content management and collaboration solutions. It recently launched Intralinks DealNexus, the largest global deal marketplace and professional network for qualified mergers and acquisitions (M&A) professionals. Intralinks DealNexus offers a secure and confidential way for dealmakers to find and engage the best buyers or capital partners, and it is used by more than 5,000 private equity firms, corporations, investment banks and advisors to intelligently connect and exchange deal opportunities. Wunderlich rates the company a stock to buy and has a $17 price objective. The consensus target is $12.The stock closed on Friday at $8.61.

Best Electric Utility Stocks For 2015: ADVA Optical Networking SE (ADV)

ADVA Optical Networking SE is a Germany-based company that develops, manufactures and sells optical and Ethernet-based networking solutions to telecommunications carriers and enterprises to deploy, manage and deliver data storage, voice and video services in metropolitan areas. Its optical transmission solutions are based on wavelength division multiplexing (WDM) technology. Its Ethernet-optimized transmission solutions for fiber- or copper-based lines are used to provide access for enterprises into a carrier's network. Its systems are used by telecommunications services providers, companies, universities and government agencies worldwide. It sells its product portfolio both directly and through an international network of distribution partners. Its optical and Ethernet-based network solutions have been deployed by more than 250 carriers and more than 10,000 enterprises. As of December 31, 2012, the Company had 13 wholly owned subsidiaries across Europe, Asia, North and Latin America. Advisors' Opinion:

• [By Holly LaFon]

  We re-established an investment in CME Group, Inc. (CME) during the period. CME is the largest and most diversified derivatives marketplace in the U.S. Its exchanges support trading across a variety of asset classes, including interest rates, equity indexes, energy, agricultural commodities, foreign exchange and metals. We believe CME has the opportunity to significantly accelerate its growth rates due to the eventual normalization of interest rates and the attendant interest rate volatility. CME's interest rate trading volumes (ADV) have been depressed as a result of the Fed's zero interest rate policy and low interest rate volatility. For example, interest rate ADV was 4.8 million in 2012compared to 7.1 million in 2007, before the financial crisis. However, given the Fed's recent policy statements (discussed above), market participants are starting to anticipate an end to quantitative easing (QE). On May 30, CME experienced record volume for interest rate derivatives with ADV of 19.4 million. With the globalization of CME's business, a host of new products, and the regulatory requirement for interest rate swaps to be cleared on an exchange, we believe CME's interest rate volumes can surpass their prior peak, significantly driving earnings growth for the company.

• [By Adrian Day]

  Adrian Day: Yes, yes, I like the concept of looking up the secondary plays. I mean, you know we own Altius (ALS) for example, rather than Alderon (ADV). Altius owns 30% of Alderon, that is more diversified, has a better balance sheet. If Alderon succeeds, Atius will succeed.

Best Diversified Bank Stocks For 2015: Sucampo Pharmaceuticals Inc (SCMP)

Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).

AMITIZA

The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.

RESCULA

The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 stock that's starting to trend within range of triggering a major breakout trade is Sucampo Pharmaceuticals (SCMP), which is engaged in the discovery, development and commercialization of proprietary drugs based on prostones, and other novel drug technologies. This stock is off to a decent start in 2013, with shares up by 26%.

  If you take a look at the chart for Sucampo Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last four months, with shares dumping hard from its high of $10.48 to its recent low of $5.40 a share. During that downtrend, shares of SCMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the downside volatility for SCMP looks to be over in the short-term since the stock has started to reverse its downtrend and enter an uptrend. That reverse is quickly pushing shares of SCMP within range of triggering a major breakout trade above a key downtrend line.

  Traders should now look for long-biased trades in SCMP if it manages to break out above some near-term overhead resistance levels at $6.33 to $6.66 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 115,383 shares. If that breakout triggers soon, then SCMP will set up to re-test or possibly take out its next major overhead resistance levels at $7.09 to $7.67 a share. Any high-volume move above those levels will then give SCMP a chance to tag $8 to $9 a share.

  Traders can look to buy SCMP off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $5.58 to $5.40 a share. One can also buy SCMP off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Diversified Bank Stocks For 2015: Entergy Corp (ETR)

Entergy Corporation (Entergy), incorporated on August 19, 1992, is an integrated energy company engaged primarily in electric power production and retail distribution operations. Entergy owns and operates power plants with approximately 30,000 megawatts of electric generating capacity, including more than 10,000 megawatts of nuclear power. Entergy delivers electricity to 2.8 million utility customers in Arkansas, Louisiana, Mississippi and Texas. Entergy operates through two business segments: Utility and Entergy Wholesale Commodities. The Utility business segment includes the generation, transmission, distribution, and sale of electric power in portions of Arkansas, Mississippi, Texas, and Louisiana, including the City of New Orleans; and operates a small natural gas distribution business. The Entergy Wholesale Commodities business segment includes the ownership and operation of six nuclear power plants located in the northern United States and the sale of the electric power produced by those plants to wholesale customers.

Utility

The Utility business segment includes six wholly-owned retail electric utility subsidiaries: Entergy Arkansas, Entergy Gulf States Louisiana, Entergy Louisiana, Entergy Mississippi, Entergy New Orleans, and Entergy Texas. These companies generate, transmit, distribute and sell electric power to retail and wholesale customers in Arkansas, Louisiana, Mississippi, and Texas. Entergy Gulf States Louisiana and Entergy New Orleans also provide natural gas utility services to customers in and around Baton Rouge, Louisiana, and New Orleans, Louisiana, respectively. Also included in the Utility is System Energy, a wholly owned subsidiary of Entergy Corporation that owns or leases 90% of Grand Gulf. System Energy sells its power and capacity from Grand Gulf at wholesale to Entergy Arkansas, Entergy Louisiana, Entergy Mississippi, and Entergy New Orleans. The electric energy sales of the Utility operating companies are subject to seasonal fluctuations, with t! he peak sales period normally occurring during the third quarter of each year. On July 30, 2012, Entergy reached a 2012 peak demand of 21,866 megawatt hour.

Entergy New Orleans and Entergy Gulf States Louisiana provide both electric power and natural gas to retail customers. During the year ended December 31, 2012, Entergy New Orleans and Entergy Gulf States Louisiana sold 8,924,256 and 6,104,341 million cubic feet, respectively, of natural gas to retail customers. In 2012, 97% of Entergy Gulf States Louisiana�� operating revenue was derived from the electric utility business, and only 3% from the natural gas distribution business. In 2002, Entergy New Orleans, 86% of operating revenue was derived from the electric utility business and 14% from the natural gas distribution business.

Entergy Wholesale Commodities

Entergy Wholesale Commodities includes the ownership and operation of six nuclear power plants, five of which are located in the Northeast United States, with the sixth located in Michigan, and is primarily focused on selling electric power produced by those plants to wholesale customers. Entergy Wholesale Commodities��revenues are primarily derived from sales of energy and generation capacity from these plants. Entergy Wholesale Commodities also provides operations and management services, including decommissioning services, to nuclear power plants owned by other utilities in the United States. Entergy Wholesale Commodities also includes the ownership of two non-operating nuclear facilities, Big Rock Point in Michigan and Indian Point 1 in New York that were acquired when Entergy purchased the Palisades and Indian Point 2 nuclear plants, respectively. The Pilgrim and Vermont Yankee and Rhode Island plants fall under the authority of the Independent System Operator (ISO) New England and the FitzPatrick and Indian Point plants fall under the authority of the New York Independent System Operator (NYISO). The Palisades plant falls under the authority of ! the MISO.! The primary purpose of ISO New England, NYISO, and MISO is to direct the operations of the major generation and transmission facilities in their respective regions; ensure grid reliability; administer and monitor wholesale electricity markets; and plan for their respective region�� energy needs.

Advisors' Opinion:

• [By Garrett Cook]

  In trading on Monday, utilities shares were relative leaders, up on the day by about 0.18 percent. Top gainers in the sector included Companhia Paranaense de Energia (NYSE: ELP), up 2.54 percent, and Entergy (NYSE: ETR), up 0.81 percent.

• [By Richard Stavros]

  The Top Low-Carbon Utilities

  PG&E Corp (NYSE: PCG) Exelon Corp (NYSE: EXC) Entergy Corp (NYSE: ETR) Public Service Enterprise Group Inc (NYSE: PEG) NextEra Energy Inc (NYSE: NEE) Dominion Resources Inc (NYSE: D) Sempra Energy (NYSE: SRE)

  But that is not to say that, over the long term, high-carbon utilities might not be able to crack the technology and cost issues that would make “clean coal” competitive with other low-carbon energy sources. Secretary of Energy Ernest Moniz has said, “No discussion of US energy security and reducing global CO2 emissions is complete without talking about coal and the technologies that will allow us to use this resource more efficiently and with fewer greenhouse gas emissions.”

• [By Richard Stavros]

  Top Utilities
  The electric utility industry typically does well in a deflationary environment, because these firms provide relative certainty of cash flows and high dividends. Here are our favorites now:
  
  Duke Energy Corp�(NYSE: DUK) is a well-run, regulated energy utility in an accommodative regulatory environment. The firm expects earnings per share (EPS) to grow 4 percent to 6 percent annually in the coming years. Management has narrowed its full-year 2013 adjusted diluted EPS guidance range to $4.25 per share to $4.45 per share. However, the company has yet to provide its 2014 earnings guidance range, or capital expenditure and cost-savings estimates for 2015 and beyond.
  
  Duke remains committed to investing in the expansion of its generational capacity in South Carolina and Florida, as well as improving the efficiency of its generational fleet in Indiana. Moreover, management hopes to improve profitability by focusing on the company�� international business operations and renewable energy sources.�
  
  NextEra Energy Inc�(NYSE: NEE) has produced one of the strongest records of earnings growth among US electric utilities, driven by its large and expanding portfolio of renewable generation at its unregulated unit, as well as load growth at regulated utility FP&L. The latter�� favorable regulatory environment and the highly hedged, clean and well-positioned wholesale generation portfolio establish a solid platform for continued earnings outperformance versus NextEra�� peers.
  
  NextEra�� third-quarter 2013 operating EPS of $1.43, up 13.5 percent from a year ago, beat analyst estimates. The results were due to the company�� effective execution of development projects, continual customer additions, and service start-up of renewable contracted projects.�
  
  Entergy Corp�(NYSE: ETR) is another steady player that has delivered consistent shareholder value over the years. The utility recently posted third-quarter 2013 oper

• [By Jon C. Ogg]

  Entergy Corp. (NYSE: ETR) was started as Neutral with a $62 price target at Goldman Sachs. Shares closed at $62.83 on Friday, in a 52-week range of $60.22 to $72.60.